These include (i) release of p53 from mortalin-p53 complexes in cancer cells, (ii) activation of nuclear translocation and reactivation of p53 activities including execution of DNA damage response, growth arrest and apoptosis and (iii) specific targeting of p53Y220C and conformational reconstitution of its wild type functions. This evidence concerns the gene TP53 and cancer.